Selection of adjuvants for vaccines targeting specific pathogens

被引:69
|
作者
Sarkar, Indranil [1 ,2 ]
Garg, Ravendra [1 ]
Littel-van den Hurk, Sylvia van Drunen [1 ,2 ]
机构
[1] Univ Saskatchewan, VIDO InterVac, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada
[2] Univ Saskatchewan, Microbiol & Immunol, Saskatoon, SK, Canada
基金
加拿大健康研究院;
关键词
Adjuvants; mechanism of action; pathogen; systems vaccinology; immunity; YELLOW-FEVER VACCINE; IMMUNE-RESPONSES; ANTIBODY-RESPONSES; SUBUNIT VACCINE; MYCOBACTERIUM-TUBERCULOSIS; INTRANASAL IMMUNIZATION; CELLULAR SIGNATURES; ADAPTIVE IMMUNITY; PARTICLE VACCINE; SYSTEMS BIOLOGY;
D O I
10.1080/14760584.2019.1604231
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Adjuvants form an integral component in most of the inactivated and subunit vaccine formulations. Careful and proper selection of adjuvants helps in promoting appropriate immune responses against target pathogens at both innate and adaptive levels such that protective immunity can be elicited.Areas covered: Herein, we describe the recent progress in our understanding of the mode of action of adjuvants that are licensed for use in human vaccines or in clinical or pre-clinical stages at both innate and adaptive levels. Different pathogens have distinct characteristics, which require the host to mount an appropriate immune response against them. Adjuvants can be selected to elicit a tailor-made immune response to specific pathogens based on their unique properties. Identification of biomarkers of adjuvanticity for several candidate vaccines using omics-based technologies can unravel the mechanism of action of modern and experimental adjuvants.Expert opinion: Adjuvant technology has been revolutionized over the last two decades. In-depth understanding of the role of adjuvants in activating the innate immune system, combined with systems vaccinology approaches, have led to the development of next-generation, novel adjuvants that can be used in vaccines against challenging pathogens and in specific target populations.
引用
收藏
页码:505 / 521
页数:17
相关论文
共 50 条
  • [41] Toll like receptors and cytokines as immunostimulatory adjuvants in poultry vaccines: current status and future trends
    Bhadouriya, S.
    Sharma, B. K.
    Kakker, N. K.
    Chhabra, R.
    WORLDS POULTRY SCIENCE JOURNAL, 2019, 75 (03) : 417 - 428
  • [42] Key roles of adjuvants in modern vaccines
    Reed, Steven G.
    Orr, Mark T.
    Fox, Christopher B.
    NATURE MEDICINE, 2013, 19 (12) : 1597 - 1608
  • [43] Immunomodulators as adjuvants for vaccines and antimicrobial therapy
    Nicholls, Erin F.
    Madera, Laurence
    Hancock, Robert E. W.
    ANTIMICROBIAL THERAPEUTICS REVIEWS, 2010, 1213 : 46 - 61
  • [44] TLR Agonists as Adjuvants for Cancer Vaccines
    Li, Ji-Kun
    Balic, Jesse J.
    Yu, Liang
    Jenkins, Brendan
    REGULATION OF INFLAMMATORY SIGNALING IN HEALTH AND DISEASE, 2017, 1024 : 195 - 212
  • [45] Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants
    Anggraeni, Rahmi
    Ana, Ika Dewi
    Wihadmadyatami, Nevi
    CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2022, 11 (03) : 235 - 248
  • [46] New Adjuvants for parenteral and mucosal Vaccines
    Guy, B
    Burdin, N
    THERAPIE, 2005, 60 (03): : 235 - 241
  • [47] Adjuvants designed for veterinary and human vaccines
    Aucouturier, J
    Dupuis, L
    Ganne, V
    VACCINE, 2001, 19 (17-19) : 2666 - 2672
  • [48] Strategies for optimizing targeting and delivery of mucosal HIV vaccines
    Ahlers, Jeffrey D.
    Belyakov, Igor M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (10) : 2657 - 2669
  • [49] Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens
    Disis, ML
    Shiota, FM
    McNeel, DG
    Knutson, KL
    IMMUNOBIOLOGY, 2003, 207 (03) : 179 - 186
  • [50] Identification of sheep lncRNAs related to the immune response to vaccines and aluminium adjuvants
    Martin Bilbao-Arribas
    Endika Varela-Martínez
    Naiara Abendaño
    Damián de Andrés
    Lluís Luján
    Begoña M. Jugo
    BMC Genomics, 22